Indicated for: type 2 diabetes mellitus
Route of administration: oral
Substance: glibenclamide + metformin (sulfonylurea antidiabetic + biguanide antidiabetic)
ATC: A10BD02 (Alimentary tract and metabolism | Blood glucose lowering drugs, excl. insulins | Combinations of oral blood glucose lowering drugs)
Dose adjustment may be needed in kidney disease.
This medicine may lower blood sugar.
Periodic laboratory tests may be required during treatment.
The combination of glibenclamide and metformin is used to treat type 2 diabetes mellitus, particularly in patients who cannot control their blood sugar levels through diet, exercise, or monotherapy alone. This combination helps lower blood glucose levels through complementary mechanisms.
- Glibenclamide is a sulfonylurea derivative that stimulates the pancreas to produce more insulin, thereby reducing blood sugar levels.
- Metformin is a biguanide that decreases glucose production in the liver, improves insulin sensitivity, and reduces glucose absorption from the digestive tract.
This combination is indicated for patients with type 2 diabetes who require stricter blood sugar control. It is essential that the treatment is accompanied by a balanced diet and regular physical activity to maximize its effectiveness.
Common side effects include nausea, diarrhea, abdominal pain, hypoglycemia (mainly due to glibenclamide), and, in rare cases, lactic acidosis (a serious complication associated with metformin). Hypoglycemia may cause symptoms such as dizziness, sweating, trembling, or confusion, and patients should be vigilant for these signs.
Patients should strictly follow their doctor’s instructions regarding dosage and regularly monitor their blood sugar levels. It is important to inform the doctor about other medications being taken or pre-existing conditions, such as kidney, liver, or heart disease, as these may affect the safety of the treatment.